These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15370275)

  • 1. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease.
    Veljkovic V; Metlas R
    Int Rev Immunol; 2004; 23(5-6):437-45. PubMed ID: 15370275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease.
    Veljkovic N; Branch DR; Metlas R; Prljic J; Manfredi R; Stringer WW; Veljkovic V
    J Clin Virol; 2004 Dec; 31 Suppl 1():S39-44. PubMed ID: 15567092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
    Veljkovic M; Branch DR; Dopsaj V; Veljkovic V; Veljkovic N; Glisic S; Colombatti A
    Med Hypotheses; 2011 Sep; 77(3):404-8. PubMed ID: 21684085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of passive immunization in hiv-positive patients : a case report.
    Veljkovic V; Metlas R; Jevtovic D; Stringer WW
    Chest; 2001 Aug; 120(2):662-6. PubMed ID: 11502675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS.
    Veljkovic V; Metlas R; Raspopovic J; Pongor S
    Biochem Biophys Res Commun; 1992 Dec; 189(2):705-10. PubMed ID: 1472041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease.
    Veljkovic N; Branch DR; Metlas R; Prljic J; Vlahovicek K; Pongor S; Veljkovic V
    J Pept Res; 2003 Oct; 62(4):158-66. PubMed ID: 12969195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection.
    Djordjevic A; Veljkovic M; Antoni S; Sakarellos-Daitsiotis M; Krikorian D; Zevgiti S; Dietrich U; Veljkovic N; Branch DR
    Curr HIV Res; 2007 Sep; 5(5):443-8. PubMed ID: 17896963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies].
    Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI
    Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive immunization for the treatment of HIV infection.
    Jacobson JM
    Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virology. Moving forward in HIV vaccine development.
    Letvin NL
    Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
    [No Abstract]   [Full Text] [Related]  

  • 13. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120.
    Veliković V; Metlas R; Danilo V; Cavor L; Pejinović N; Dujuć A; Zakhariev S; Guarnaccia C; Pongor S
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1019-24. PubMed ID: 8250861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors.
    Wang Q; Shang H; Han X; Zhang Z; Jiang Y; Wang Y; Dai D; Diao Y
    Microbiol Immunol; 2008 Apr; 52(4):209-15. PubMed ID: 18426395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
    Herbeuval JP; Shearer GM
    AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?
    Klasse PJ; Moore JP
    Virology; 2004 May; 323(1):1-8. PubMed ID: 15165814
    [No Abstract]   [Full Text] [Related]  

  • 18. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection.
    Vieillard V; Costagliola D; Simon A; Debré P;
    AIDS; 2006 Sep; 20(14):1795-804. PubMed ID: 16954720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving on nature: focusing the immune response on the V3 loop.
    Zolla-Pazner S
    Hum Antibodies; 2005; 14(3-4):69-72. PubMed ID: 16720976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies.
    Nishiyama Y; Karle S; Mitsuda Y; Taguchi H; Planque S; Salas M; Hanson C; Paul S
    J Mol Recognit; 2006; 19(5):423-31. PubMed ID: 16838382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.